Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe

•Genomic profiling assays for early breast cancer have excellent prognostic capacities.•There is large variation in the quantity and quality of economical and clinical evidence.•OncotypeDX and MammaPrint have been validated in prospective (randomized) clinical trials.•Subgroups for which genomic pro...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cancer treatment reviews 2018-01, Vol.62, p.74-90
Hauptverfasser:	Blok, E.J., Bastiaannet, E., van den Hout, W.B., Liefers, G.J., Smit, V.T.H.B.M., Kroep, J.R., van de Velde, C.J.H.
Format:	Artikel
Sprache:	eng
Schlagworte:	Breast cancer Endopredict Gene expression MammaPrint OncotypeDX Prosigna
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!